Filing Details

Accession Number:
0001562180-22-006777
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-20 20:23:33
Reporting Period:
2022-09-12
Accepted Time:
2022-09-20 20:23:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1603756 Axonics Inc. AXNX Surgical & Medical Instruments & Apparatus (3841) 454744083
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1756240 Karen Noblett 26 Technology Drive
Irvine CA 92618
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-12 18,519 $14.19 50,118 No 4 M Direct
Common Stock Acquisiton 2022-09-12 13,964 $25.82 64,082 No 4 M Direct
Common Stock Disposition 2022-09-12 32,483 $78.16 31,599 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-09-12 18,519 $0.00 18,519 $14.19
Common Stock Stock Options (Right to buy) Disposition 2022-09-12 13,964 $0.00 13,964 $25.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,963 2029-01-30 No 4 M Direct
6,348 2029-12-12 No 4 M Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $78.00 to $78.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.
  3. The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.